Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF6001 add-on to triple therapy in COPD with chronic bronchitis
NL-OMON56320Phase 3Recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tanimilast in chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB) (4 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Rate of moderate and severe COPD exacerbations over 52 weeks. Started Jan 2022; status: recruiting.
02
Drugs
tanimilast
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
Beyond the preview
Go deeper on NL-OMON56320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56320.